Biological Therapy in Noninfectious Pediatric Uveitis: A Systematic Review

Figures & data

Figure 1 Review flowchart.

Table 1 Characteristics of the Included Studies

Study	Type	Center	Local	Follow-Up (Months)	Age (Averageor Age Group)	Sex (F/M)	Intervention	N	Dose	Control	N	Dose
Quartier 2017^Citation20	RCT	9	France	12	10.8 ADA 9.2 PL	28/3	ADA	16	40mg/m^2 > 13y 24 mg/m^2 < 13y	Placebo	15	NR^b + MTX (0.3–0.6 mg/Kg without exceeding 25mg/w)
Ramanan 2017^Citation21	RCT	14	United Kingdom	24	9.07 ADA 8.56 PL	70/20	ADA	60	40 mg/m^2 >30Kg 20 mg/m^2 <30Kg	Placebo	30	0.8mL + MTX (10–20 mg/m^2 without exceeding 25mg/w)
Smith 2005^Citation19	RCT	1	USA	12	11	9/3	ETA	7	0.4 mg/Kg	Placebo	5	NR^b + MTX (≤ 1 mg/Kg/w without exceeding 25mg/w) or PD (≤ 1 mg/Kg/d)
Cecchin 2018^Citation26	NRS P	24	Italy	24	9.5	1/4,3	ADA	95	1mg/kg	IFX	59	5 mg/Kg
Simonini 2011^Citation23	NRS P	3	Italy	12–40	9.2	22/11	ADA	16	24 mg/m^2	IFX	17	5 mg/Kg
Zannin 2013^Citation24	NRS P	NR^a	Italy	12	9.7	71/20	ADA	43	1 mg/Kg (máx 40mg)	IFX	48	5 mg/Kg
Tynjälä 2007^Citation22	NRS R	3	Finland	24	9.8	39/8	ETA	24	0.4 mg/Kg	IFX	21	3–6 mg/Kg
Gaidar 2014^Citation25	NRS R	1	Russia	3–48	5–17	27/10	ADA	28	40 mg/m^2	IFX	9	5–6 mg/Kg
Gunduz 2021^Citation27	NRS R	1	Turkey	12–50	12.5 ADA 15.2 IFX	19/14	ADA	17	40 mg ≥ 30 Kg 20 mg < 30 Kg	IFX	16	5 mg/Kg

Notes: ^aMulti-center (number not reported). ^b(placebo dose not reported).

Abbreviations: RCT, randomized clinical trial; P, prospective; R, retrospective; PL, placebo; ADA, adalimumab; IFX, infliximab; ETA, etanercept; NR, not reported; NRS, non-randomized study; PD, prednisone; MTX, methotrexate.

Figure 2 Summary of risk of bias from randomized clinical trials. Review the authors’ judgments about each item of risk of bias for each study included in the meta-analysis.

Figure 3 Summary of risk of bias from non-randomized controlled trials.

Figure 4 Comparison: Anti-TNF-α versus placebo. Outcome: Satisfactory response rate to treatment.

Figure 5 Comparison: Adalimumab versus placebo. Outcome: Satisfactory response rate to treatment.

Figure 6 Comparison: Adalimumab versus placebo. Outcome: Reduction or interruption of the use of corticosteroids.

Figure 7 Comparison: Adalimumab versus infliximab. Outcome: Satisfactory response rate to treatment.

Figure 8 Comparison: Adalimumab versus infliximab. Outcome: occurrence of local and systemic adverse events.

Figure 9 Summary of findings for the comparison of anti-TNF-α versus placebo. Outcome: Satisfactory response to treatment.

Figure 10 Summary of findings for the comparison of adalimumab versus placebo. Outcome: Satisfactory response to treatment.

Figure 11 Summary of findings for the comparison of adalimumab versus placebo. Outcome: Reduction or discontinuation of corticosteroids use.

Figure 12 Summary of findings for the comparison of adalimumab versus infliximab. Outcome: Satisfactory response to treatment.

Figure 13 Summary of findings for the comparison of adalimumab versus infliximab. Outcome: Local and systemic adverse events.

Quartier P, Baptiste A, Despert V, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early-onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2017;77:1–9.

 Google Scholar

Ramanan AV, Dick AD, Jones AP, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376(17):1637–1646. doi:10.1056/NEJMoa1614160

 PubMed Web of Science ®Google Scholar

Smith JA, Thompson DJS, Whitcup SM, et al. A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005;53:18–23. doi:10.1002/art.20904

 PubMed Web of Science ®Google Scholar

Cecchin V, Zannin ME, Ferrari D, et al. Long-term Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis. J Rheumatol. 2018;45(8):1167–1172. doi:10.3899/jrheum.171006

 PubMed Web of Science ®Google Scholar

Simonini G, Taddio A, Cattalini M, et al. Prevention of flare recurrences in childhood-refractory chronic uveitis: an open-label comparative study of adalimumab versus infliximab. Arthritis Care Res. 2011;63:612–618. doi:10.1002/acr.20404

 PubMed Web of Science ®Google Scholar

Zannin ME, Birolo C, Gerloni VM, et al. safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year follow-up data from the Italian Registry. J Rheumatol. 2013;40(1):74–79. doi:10.3899/jrheum.120583

 PubMed Web of Science ®Google Scholar

Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007;66(4):548–550. doi:10.1136/ard.2006.058248

 PubMed Web of Science ®Google Scholar

Gaidar EV, Kostik MM, Snegireva LS, et al. Outcomes of treatment of juvenile idiopathic arthritis related uveitis with TNF-alpha inhibitors. Pediatrician. 2014;5:60–64.

 Google Scholar

Gunduz GU, Yalcinbayir O, Cekic S, Yildiz M, Kilic SS. Anti-Tumor Necrosis Factor Treatment in the Management of Pediatric Noninfectious Uveitis: infliximab Versus Adalimumab. J Ocul Pharmacol Ther. 2021;37:1–5.

 Web of Science ®Google Scholar